

ALG9 Antibody (C-term) Blocking peptide
Synthetic peptide
Catalog # BP10159b

Specification

ALG9 Antibody (C-term) Blocking peptide - Product Information

Primary Accession [O9H6U8](#)
Other Accession [NP_001071159.1](#), [NP_001071160.1](#),
[NP_001071158.1](#), [NP_079016.2](#)

ALG9 Antibody (C-term) Blocking peptide - Additional Information

Gene ID 79796

Other Names

Alpha-1, 2-mannosyltransferase ALG9, Asparagine-linked glycosylation protein 9 homolog, Disrupted in bipolar disorder protein 1, Dol-P-Man:Man(6)GlcNAc(2)-PP-Dol alpha-1, 2-mannosyltransferase, Dol-P-Man:Man(8)GlcNAc(2)-PP-Dol alpha-1, 2-mannosyltransferase, ALG9, DIBD1

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

ALG9 Antibody (C-term) Blocking peptide - Protein Information

Name ALG9 ([HGNC:15672](#))

Function

Mannosyltransferase that operates in the biosynthetic pathway of dolichol-linked oligosaccharides, the glycan precursors employed in protein asparagine (N)-glycosylation. The assembly of dolichol-linked oligosaccharides begins on the cytosolic side of the endoplasmic reticulum membrane and finishes in its lumen. The sequential addition of sugars to dolichol pyrophosphate produces dolichol-linked oligosaccharides containing fourteen sugars, including two GlcNAcs, nine mannoses and three glucoses. Once assembled, the oligosaccharide is transferred from the lipid to nascent proteins by oligosaccharyltransferases. In the lumen of the endoplasmic reticulum, catalyzes the addition of the seventh and ninth alpha-1,2-linked mannose residues to Man(6)GlcNAc(2)-PP-dolichol and Man(8)GlcNAc(2)-PP- dolichol respectively.

Cellular Location

Endoplasmic reticulum membrane; Multi-pass membrane protein
{ECO:0000250|UniProtKB:P53868}

Tissue Location

Ubiquitously expressed; with highest levels in heart, liver and pancreas.

ALG9 Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

ALG9 Antibody (C-term) Blocking peptide - Images**ALG9 Antibody (C-term) Blocking peptide - Background**

This gene encodes an alpha-1,2-mannosyltransferase enzyme that functions in lipid-linked oligosaccharide assembly. Mutations in this gene result in congenital disorder of glycosylation type II. Multiple transcript variants encoding different isoforms have been found for this gene.

ALG9 Antibody (C-term) Blocking peptide - References

Vleugels, W., et al. *Glycobiology* 19(8):910-917(2009) Baysal, B.E., et al. *Behav Brain Funct* 2, 25 (2006) : Weinstein, M., et al. *Am. J. Med. Genet. A* 136(2):194-197(2005) Frank, C.G., et al. *Am. J. Hum. Genet.* 75(1):146-150(2004) Baysal, B.E., et al. *Neurogenetics* 4(1):43-53(2002)